

RWANDA PENTAVALENT VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant Number: 0715-RWA-04c-X			
3. Date of Decision Letter: 18 December 2014			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme Title: NVS, Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2002 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2002-2014	2015	Total ²
Programme Budget (US\$)	US\$42,265,255 ³	US\$2,036,500	US\$44,301,755
10. Vaccine Introduction Grant: Not applicable			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2002-2014	2015	
Number of Pentavalent vaccines doses		997,500	
Number of AD syringes		1,127,400	
Number of safety boxes		12,425	
Annual Amounts (US\$)	US\$42,265,255 ⁵	US\$2,036,500	
12. Procurement agency: UNICEF			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 0715-RWA-04c-X-C

According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	214,500
Value of vaccine doses (US\$)	US\$410,260
Total Co-Financing Payments (US\$) (including freight)	US\$424,500

15. Operational support for campaigns: Not applicable

16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015

17. Financial Clarifications: No applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
18 December 2014

RWANDA PNEUMOCOCCAL VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant Number: 0915-RWA-12c-X			
3. Date of Decision Letter: 18 December 2014			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID			
8. Programme Duration ¹ : 2009 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2009-2014	2015	Total ²
Programme Budget (US\$)	US\$22,370,703 ³	US\$4,091,000	US\$26,461,703
10. Vaccine Introduction Grant: Not applicable			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement): ⁴ The Annual Amount for 2015 has been amended.			
Type of supplies to be purchased with Gavi funds in each year	2009-2014	2015	
Number of Pneumococcal vaccines doses		961,200	
Number of AD syringes		1,148,300	
Number of safety boxes		12,650	
Annual Amounts (US\$)	US\$22,370,703 ⁵	US\$4,091,000	
12. Procurement agency: UNICEF			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable									
14. Co-financing obligations: Reference code: 0915-RWA-12c-X-C									
According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.									
<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>104,400</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$352,090</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$373,000</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	104,400	Value of vaccine doses (US\$)	US\$352,090	Total Co-Financing Payments (US\$) (including freight)	US\$373,000
Type of supplies to be purchased with Country funds in each year	2015								
Number of vaccine doses	104,400								
Value of vaccine doses (US\$)	US\$352,090								
Total Co-Financing Payments (US\$) (including freight)	US\$373,000								
15. Operational support for campaigns: Not applicable									
16. Additional documents to be delivered for future disbursements:									
<table border="1"> <thead> <tr> <th>Reports, documents and other deliverables</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Annual Progress Report or its equivalent.</td> <td>15 May 2015</td> </tr> </tbody> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent.	15 May 2015				
Reports, documents and other deliverables	Due dates								
Annual Progress Report or its equivalent.	15 May 2015								
17. Financial Clarifications: Not applicable									
18. Other conditions: Not applicable									

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
18 December 2014

RWANDA ROTAVIRUS VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Rwanda			
2. Grant Number: 1215-RWA-13a-X			
3. Date of Decision Letter: 18 December 2014			
4. Date of the Partnership Framework Agreement: 7 June 2013			
5. Programme Title: NVS, Rotavirus Routine			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 3 dose(s) schedule			
8. Programme Duration¹: 2012 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2012-2014	2015	Total ²
Programme Budget (US\$)	US\$18,231,505 ³	US\$2,247,000	US\$20,478,505
10. Vaccine Introduction Grant: Not applicable			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2012-2014	2015	
Number of Rotavirus vaccines doses		428,000	
Annual Amounts (US\$)	US\$18,231,505 ⁵	US\$2,247,000	
12. Procurement agency: UNICEF			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 1215-RWA-13a-X-C

According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	30,600
Value of vaccine doses (US\$)	US\$152,850
Total Co-Financing Payments (US\$) (including freight)	US\$160,500

15. Operational support for campaigns: Not applicable

16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015

17. Financial Clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
18 December 2014

RWANDA - HPV VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1.	Country: Rwanda				
2.	Vaccines Grant Number: 1417-RWA-19b-X Cash Support Grant Number: n/a				
3.	Date of Decision Letter: 09 December 2014				
4.	Date of the Partnership Framework Agreement: 07 June 2013				
5.	Programme Title : New Vaccine Support				
6.	Type of vaccine : HPV				
7.	Requested product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose(s) per vial, LIQUID				
8.	Programme Duration: 2014-2017 ¹				
9.	Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement):				
	2014	2015	2016	2017	Total²
Programme Budget (US\$)	US\$2,895,500	US\$1,408,000	US\$958,500	US\$918,000	US\$6,180,000
10.	Vaccine Introduction Grant: n/a				
11.	Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):²				
	Type of supplies to be purchased with Gavi funds in each year	2014	2015		
	Number of HPV vaccines doses		296,900		
	Number of AD syringes		322,900		
	Number of safety boxes		3,575		
	Annual Amounts (US\$)	US\$2,895,500	US\$1,408,000		

¹ This is the entire duration of the programme.

² This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

12. Procurement agency: UNICEF			
13. Self-procurement: n/a			
14. Co-financing obligations: reference code : 1417-RWA-19b-X-C			
<p><i>According to the Co-Financing Policy, the Country falls within the Low Income group. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</i></p>			
Type of supplies to be purchased with Country funds in each year	2015	2016	2017
Number of vaccines doses	13,300	9,000	13,000
Value of vaccine doses (US\$)	US\$59,775		
Total Co-Financing Payments (US\$) (Including freight)	US\$62,500	US\$42,500	US\$50,000
15. Operational support for campaigns: n/a			
16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:			
Reports, documents and other deliverables		Due dates	
Annual Progress Report or equivalent		To be agreed with GAVI Secretariat	
17. Financial Clarifications: the Country shall provide the following clarifications to Gavi*: n/a			
<i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>			
18. Other conditions: The Country shall provide an update on the implementation of recommendations of the aide-memoire			

Signed by



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

16 December 2014